In type 1 diabetes, insulin remains the mature therapeutic cornerstone; yet, the increasing
number of individuals developing type 1 diabetes (predominantly children and adolescents) …

Although type 1 diabetes is traditionally considered a disease of lean people, overweight
and obesity are becoming increasingly more common in individuals with type 1 diabetes …

Background Comparative effectiveness of 7 glucagon-like peptide 1 (GLP-1) agents on
weight loss (WL) in obesity remains unknown. Methods We performed a systematic review …

Aims To explore the effect of glucagon-like peptide-1 receptor agonist (GLP-1 RAs) on
glycemic control and weight reduction in adults. Methods Databases were searched from …

Incretin-based therapies, in particular glucagon-like peptide-1 (GLP-1) receptor agonists,
have been evaluated in other forms of diabetes, but randomised controlled trials are mainly …

Currently, gastrointestinal hormone glucagon like peptide-1 (GLP-1) has received significant
attention in maintaining glucose homeostasis through mechanisms involving augmentation …

Aim The cardiovascular benefits provided by glucagon‐like peptide‐1 receptor agonists
(GLP‐1RAs) extend beyond weight reduction and glycaemic control. One possible …

The prevalence of overweight and obesity among youth patients with diabetes type 1 is
increasing. It is estimated, that even up to 35% of young patients with this type of diabetes …

Exogenous insulin has been the mainstay treatment for individuals living with type 1
diabetes (T1D). Although there has been tremendous growth in both pharmacological and …

Context Concomitant obesity is common amongst patients with type 1 diabetes mellitus
(T1DM), yet adjunctive therapy options are scarce. Objective We assess the efficacy and …